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1. Introduction 
Chemoresistance is a complex mechanism, involving various biological pathways. Also, 
chemoresistance is a major cause of cancer treatment failure. Cancer stem cell (CSC) in solid 
cancer has recently identified, but its role in solid organ tumour is not clearly documented. 
However, research data supported that CSC may involve in carcinogenesis, invasion and 
metastasis, as well as resistance to various form of chemotherapy. Understanding more how 
CSCs involve in chemoresistance would enhance our knowledge and thus would lead us to 
the possibly newly developed cancer treatment.  
2. Stem cells and clinical relevance to therapy 
Stem cells are a small and distinct population of cells in living body. Stem cells can divide, 
and can produce progeny of differentiated cells with specific functions, therefore, have two 
major key characteristics: 1) capacity for asymmetric division or self-renewal and 2) generate 
a quiescent stem cell that can produce “progenitor” cells, which can differentiate into more 
mature and differentiated cells.  
Self-renewal is a characteristic process of stem cells, thereby, ensuring that the stem cells 
survive a long time. All stem cells must regulate the balance between self-renewal and 
differentiation. The self-renewal and differentiation of stem cells is regulated by many 
signalling pathways, and some pathways are associated with carcinogenesis including 
Notch, Shh, BMI 1 and Wnt signalling pathways [Jordan, 2004].  In fact, some of these 
proteins (eg. Wnt) has become therapeutic target [Takahashi-Yanaga and Kahn, 2010].   
In general, human stem cells can be classified broadly into embryonic, foetal and adult stem 
cells. Adult stem cells have limited potential for differentiation into different cell types of 
their tissue of origin whereas embryonic stem cells can differentiate into all cell phenotypes 
[Bellantuono and Keith, 2007]. Most adult tissue-specific stem cells are traditionally believed 
to be multipotent, but not pluripotent. However, recent data has documented that adult 
stem cells can show plasticity, and that the adult tissue-restricted stem cells may develop 
into cells resembling pluripotent stem cells [Askenasy et al., 2006;Kiger et al., 
2000;Bellantuono and Keith, 2007].   
Recently, stem cell research has been expanding rapidly, not only in basic scientific research 
but also in clinical research. Treatment of many complex diseases with stem cell is more 
widely used in various types of haematologic diseases, including thallasemia, aplastic 
anemia and other hematologic malignancies. As well, stem cell has increasing roles in the 
www.intechopen.com
 Cancer Stem Cells Theories and Practice 
 
414 
treatment of other non-haematologic diseases including heart failure, liver dysfunctions and 
neurodegenerative diseases [Chang and Appasani, 2006;Dimarakis et al., 2005;Gordon et al., 
2006;Burt et al., 2008]. 
Better understanding about stem cells has started from the studies of haematopoietic tissues. 
In the haematopoiectic system a wide variety of blood cells in the circulation appear to 
originate from the same precursors [Huntly and Gilliland, 2005]. With this observation, later 
identification of haematologic stem cells was achieved. The rapid further advancement in 
haematopoietic stem cell knowledge has later made haematopoietic stem cell 
transplantation become a standard treatment for various haematologic diseases, with a good 
and safe outcome [Ikehara, 2003]. Therefore, approval of stem cell therapy is limited 
primarily to haematologic diseases. Treatment of other degenerative diseases with stem cell 
therapy is possibly only in the research area, but with a potential expand to clinical practice 
in the near future. For example, recent published data has used human CD34+ adult bone 
marrow stem cells for the treatment of chronic liver disease and has shown an impressive 
outcome [Gordon et al., 2006;Levicar et al., 2008]. Haematopoietic stem cells have also being 
used in many clinical (Phase I) trails in the treatment of ischaemic heart disease, diabetes 
and other neurodegenerative diseases with an impressive preliminary outcome [Balsam and 
Robbins, 2005;Dimarakis et al., 2005;Levicar et al., 2007]. However, long-term outcome 
clinical data has still to be documented and carefully evaluated.   
3. Cancer stem cells: a small population in tumours 
Most cancer cells grow and divide rapidly and indefinitely, as well as stem cells. This 
observation has led to the possible link between cancer cell and stem cell. In fact, knowledge 
about cancer stem cell (CSC) become widely accepted following the work of John Dick and 
his colleagues in 1994 who described the presence of CSCs in haematologic malignancies 
[Lapidot et al., 1994]. The concepts of CSCs arose from the observations of the capacity to 
and comparability of self-renewal between stem cells and cancer cells. As a result, CSCs are 
believed to be involved in carcinogenesis, as well as in local invasion and in the metastatic 
process [Glinsky et al., 2005; Spillane and Henderson, 2007]. As well, there is also 
accumulating data supported that stem cells play an important role in chemo- and 
radiotherapy resistance [Dean et al., 2005].   
In the seminal experiment in 1960, patients had their own tumour cells injected into their 
body subcutaneously. A low success rate of tumour growth occurred at the injection site 
(14.3%), with a large number of cancer cells (at least 1 x 106 cells) required in order to induce 
a tumour growth at the autotransplantation site [Southam and Brunschwig, 1960]. At that 
time, the explanation as to why cancer cells isolated from malignant tumours could not 
regenerate on reinjection was unclear. However, with the recent knowledge about CSC, an 
explanation for the results of the experiment may be the small percentage of CSCs in the 
tumour inoculations. Out of the 1 x 106 cells that implanted into his patients, less than 0.5% 
consisted of CSCs. This small population of stem cells was able to induce growth and form a 
tumour at the injection site. Thus, the reason as to why at least 1 x 106 cells were required for 
the implantation in order to generate a new tumour.  
4. Breast cancer stem cells  
The success to identify CSCs in haematologic malignancies has led to the discovery of stem 
cells in solid tumours, which later has enhanced our knowledge of cancer biology. Amongst 
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the study of CSC in solid organ malignancies, breast CSC is one of the most widely 
investigated.  In normal breast epithelium, there are two main cell types, known as  luminal 
epithelial and myoepithelial cells. The stem cell populations reside in the luminal, but not in 
the myoepithelial compartment [Gudjonsson and Magnusson, 2005]. As a result of 
mutations in the stem/progenitor cells, normal breast stem/progenitor cells are transformed 
into breast CSCs/progenitor cells [Beier et al., 2007;Ricci-Vitiani et al., 2007].  
Previously, identification and isolation of stem cells in solid organ tumour was not possible. 
Until recently, identification and isolation of CSCs from the other cell populations was 
succeeded due to development of newly discovered cell surface biomarkers and 
advancement of biomolecular technology (ie. flow cytometery). Stem cells identified from 
solid tumours express organ-specific cell surface markers. For example, 
EpCAM(high)/CD44(+)/CD166(+) is a specific marker for the human colon CSCs [Dalerba 
et al., 2007] and CD133 is the specific stem cell marker for human central nervous system 
cancers [Beier et al., 2007]. Breast CSCs were first identified by Al-Hajj et al (2003) who 
established that the CD44(+)/CD24(-) was the surface phenotypic profile of breast CSCs [Al-
Hajj et al., 2003].  A small number of CD44(+)/CD24(-) cells (as few as 200 cells) were able to 
give rise to new tumours after injection into the mammary fat pad of NOD/SCID mice [Al-
Hajj et al., 2003]. These findings have been confirmed subsequently by other research [Ponti 
et al., 2005]. 
CD44 is a 37 kDa cell adhesion molecule expressed in most cell types, including putative 
breast CSCs [Goodison et al., 1999]. CD24 was originally found during the early stage of B 
cell development and is highly expressed in neutrophils, but not in normal T cells or 
monocytes [Balic et al., 2006]. The gene studies of CD44+ cells, extracted from human breast 
tissues, have shown the expression of genes associated with self-renewal, including 
hedgehog signaling pathway-related genes – Gli1 and Gli2 [Shipitsin et al., 2007]. As well, 
the TGF-β signalling pathway, known to be important in human embryonic stem cells and 
promoting invasion and angiogenesis, was found to be activated in CD44(+) breast cancer 
cells [Shipitsin et al., 2007]. These findings have suggested that CD44 (+) expressing cells 
that are CD24(-) are CSCs and have supported the probable role(s) of CSCs in determination 
of biological aggressiveness and invasive behaviour. 
In addition, recently, aldehyde dehydrogenase 1 (ALDH 1) has been used as another marker 
to identify breast CSCs. ALDH1 is a detoxificating enzyme responsible for the oxidation of 
intracellular aldehydes [Duester, 2000]. As few as 20 breast cancer cells with CD44+/CD24- 
/ALDH+ were able to generate tumours in NOD/SCID mice [Ginestier et al., 2007].  
Success in identifying and isolation of CSC in breast cancer is probably a breakthrough in 
cancer research and that make scientist can study further the roles of CSC in cancer biology 
more easily. 
5. Anti-cancer chemotherapy resistance 
Nowadays, treatment of cancer consists of various modalities, including surgery, radio-, 
chemo-therapy and others. However, in order to achieve the maximum systemic control, 
one of the most crucial modalities is chemotherapy. Therefore, resistance to chemotherapy is 
a major cause of failure in the treatment of solid organ malignancies. Mechanisms involved 
to resistance process are complex and not fully understood. The following mechanisms are 
proposed to be involved in chemotherapy resistance.   
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5.1 ABC transporters and multidrug resistance  
Chemotherapeutic drug resistance includes the efflux/influx of drugs via the adenosine 
triphosphate-binding cassette (ABC) transporters.  These cell membrane proteins include 3 
main types – P-gp (ABCB1/multi-drug resistance (MDR) 1), MDR-associated protein 
(MRP1/ABCC1) and breast cancer resistance protein (BCRP/ABCG2).  The ABC transporter 
system has been conserved across the phylogenic spectrum, from bacteria to mammals, and 
through evolution.  The main function of ABC transporters is to excrete toxins from the 
liver, kidneys and gastrointestinal tract.  In addition, ABC transporters act as a filter for 
toxins which enter certain vital structures such as the brain, placenta and testes.  ABC 
transporters are thought to play a crucial role in chemotherapeutic agent resistance 
mechanisms by effluxing drugs out of tumour cells.  Consequently, intracellular drug 
concentrations may fluctuate and be low.  To date, more than 40 ABC transporter genes 
have been discovered and are classified into 8 subfamilies:  ABCA through ABCG and 
ANSA (arsenite and antimonite transporter) [Mahadevan and List, 2004]. 
ABC transporter subfamily A (ABCA) gene consists of 13 members that have various roles 
in the cell membrane.  ABC transporter subfamily B, also known as MDR, comprises 11 
members.  The best characterised is P-gp (MDR1/ABCB1), a 170 kDa glycoprotein encoded 
by the MDR1 gene.  The ABC transporter subfamily C is also known as MRP, with currently 
at least nine members (MRP1-9) having been identified and related closely to 
chemoresistance mechanisms [Hopper-Borge et al., 2004].  BCRP is another protein 
associated with chemoresistance mechanisms.  It is a member of the ABC transporter 
subfamily G.  It is named “BCRP” because it was originally isolated from the MCF-7 breast 
cancer cell line; it is not only found in breast cancer, but is also detected in various types of 
chemoresistant malignancies. 
In cancer cells, over-expression of P-gp correlates with resistance to anthracyclines, vinca 
alkaloids, colchicines, epipodophyllotoxins and taxanes [Avendano and Menendez, 2002].  
Over-expression of P-gp is associated with many chemoresistant cancers including lymphoma, 
acute leukaemia, breast cancer, ovarian and head and neck cancer [Sauna et al., 2001]. A study 
of more than 400 tumour specimens of colon, renal, adrenal, liver and pancreas, showed that 
patients with increased levels of MDR1 RNA tended to be more resistant to chemotherapy 
[Goldstein et al., 1989]. A meta-analysis review by Trock et al (1997) indicated that the 
proportion of breast tumours expressing P-gp of the various studies was 41.2%. Moreover, the 
same study claimed that breast cancer patients who had tumours expressing P-gp were three 
times more likely to be chemoresistant [Trock et al., 1997].  
In the human normal cell, BCRP can be detected in the heart, ovary, kidney and foetal liver 
[Allikmets et al., 1998]. Cell lines selected for resistance to mitoxantrone, topotecan, 
doxorubicin, SN-38 (the active metabolite of irinotecan), flavopiridol and indolocarbazole 
topoisomerase I inhibitors, all over-expressed BCRP. However, typical substrate of P-gp 
such as vinca alkaloids, paclitaxel and verapamil are not transported by BCRP [Allen and 
Schinkel, 2002]. Expression of BCRP was seen in all tumour types, but was more common in 
adenocarcinomas of the GI tract, endometrium, lung, and melanoma [Diestra et al., 2002].   
5.2 Detoxification enzyme involving in chemotherapy resistance 
Three phases of drug detoxification are responsible for excretion of toxic substances from 
the cell. Phase I detoxification is usually mediated by cytochome P450 and results in 
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eliminating OH forming free radicals. Phase II is generally involved in converting 
metabolites to less toxic agents. During phase II, toxic substances will conjugate with 
glutathione, glucuronic acid or sulphate, which will be catalyzed by glutathione S-
transferase, uridine diphosphate-glucuronosyl transferase, and sulfatase. Finally, exporting 
the toxic drug with its metabolites out of the cells via transmembrane efflux pumps is the 
main activity that occurs during phase III detoxification.  Therefore, impairment of 
detoxification process is directly linked to impairment of chemotherapeutic agent activation, 
thus involves to chemotherapy resistance. 
5.3 Inactivation of apoptosis 
The deregulation or inactivation of apoptosis in a cell is crucial to the subsequent 
development of cancer in that cell.  This malfunction of the apoptotic process may 
predispose the cell to resistance to chemotherapeutic agents, as induction of apoptosis is a 
key element of drug-induced cancer cell death.  The apoptosis is thought to be mediated by 
the tumour-suppressor protein p53.  It prevents tumourigenesis by acting as a cellular-stress 
and DNA-damage sentinel.  As a result of DNA damage, hypoxia or proliferating signals, 
p53 stabilizes causing cells to undergo cell cycle arrest (checkpoint function) temporarily or 
permanently, or apoptosis and death [Levine, 1997]. 
Most human cancers have either mutations in p53 or defects in p53 regulated pathways [Lowe 
et al., 1994; Vousden and Lu, 2002]. p53 null mice are very prone to developing cancers 
[Attardi and Donehower, 2005]. Most cancer therapies are DNA-damaging agents, thus, if the 
cancer cells have a disabled/deregulated apoptotic pathway (p53 mutation or over-expression 
of BCL-2 protein), this will prevent death of the cancer cell through drug-induced apoptosis. 
Therefore, there probably is a non-apoptotic dependent pathway of cell death. Clonogenic 
survival assays in mice have failed to reveal any differences between rates of cell death of 
normal and malignant cells to ionising radiation, implying that there are other pathways for 
cancer cell death. This suggests that those cancers carrying the Tp53 allele or over-expressing 
the anti-apoptotic protein BCL-2 should be more resistant to cancer drug therapy than tumour 
cells with intact apoptotic pathways (presence of wild type 53, low levels of BCL-2). This has 
not been shown to be the case for non-haematological malignancies. 
In a recent review, there was no clear evidence that either the apoptotic index or levels of 
p53, BCL-2 or other homologous proteins are predictive of the response of solid tumours to 
chemotherapy or radiotherapy [Schmitt and Lowe, 1999;Brown and Wilson, 2003].  Apart 
from apoptosis, cells can be eliminated following DNA damage by necrosis, mitotic 
catastrophe (giant or multinucleated cells), autophagy (self-cell digestion) with intracellular 
vacuoles containing ribosomes, and premature senescence. 
The precise pathway of cell death as a result of drug treatment is difficult to determine and 
is dependent on a range of factors, including tumour cell type and volume, drug 
combinations and doses used as well as activated anti-cancer host defences. 
6. Role of cancer stem cells in chemoresistance 
One characteristic of CSCs that differentiates them from other normal cells in the tumour is 
that CSCs have high levels of ABC transporter proteins. These transporter molecules are 
responsible for protecting cells from drug damage via the efflux pumping mechanisms. 
Thus, CSCs, as a result of these biological properties, are resistant to drug treatment,  
including chemotherapeutic drugs [Dean et al., 2005].   
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In clinical practice, optimal chemotherapy treatment can kill most cells within solid tumour. 
However, a small fraction of cells (CSCs) are drug resistant, possibly because of enrichment 
of ABC transporter proteins. This small fraction of CSCs remain quiescent in the G0 phase. 
Over a period of time and due to stimuli associated with tumour cell death, these quiescent 
stem cells give rise to progenitor cells and subsequently become new mature tumour cells 
with a chemoresistant phenotype. This is the postulated model of acquired chemoresistance 
in breast cancer observed in the clinic [Dean et al., 2005]. Patients at this stage will develop 
recurrent tumours and fail to be responsive to further chemotherapy treatment.  
The high expression of ABC transporter protein in tumour stem cells results in exclusion of 
the fluorescent dye Hoechst 33342 and Rhodamine 123, and can be detected by flow-
cytometry. The cells that are able to efflux Hoechst 33342 as detected on flow-cytometry are 
known as the “side population” (SP) cells.  However, some drug resistant non-stem cells 
have these properties as well. Stem cells also have an active DNA repair capacity and a 
resistance to apoptosis. 
In addition, as previously evidenced, CSCs are believed to have overexpression of ALDH1, 
a detoxification enzyme [Lugli et al., 2010;Neumeister et al., 2010]. However, ALDH1 alone 
is not specific marker for stem cells [Neumeister and Rimm, 2010]. For example, in a study 
of breast CSC, as few as 500 ALDH1 positive cells can generate a new tumour; whist as few 
as 20 CD44+/CD24-/lin-/ALDH1+ cells can induce a new tumour [Ginestier et al., 2007].  
The linkage between CSCs and chemoresistance is an interesting and challenging area of 
research. The ability to identify CSCs in tumours and perhaps to kill these cells is a 
therapeutic strategy designed to overcome cancer chemoresistance. However, the 
knowledge and evidence regarding the contribution of CSCs to chemoresistance is still 
embryonic and requires further careful evaluation. 
7. Strategies to overcome chemoresistance by targeting cancer stem cells 
If the chemoresistant cells are CSCs, targeting treatment at these cells would be the way 
forward to overcome the chemoresistance and could improve the outcome of breast cancer 
treatment. The traditional approach of changing chemotherapeutic regimens, after tumours 
develop resistance to one chemotherapeutic regimen, may not be useful in chemoresistant 
breast cancers. Most current chemotherapeutic drugs are targeted on rapidly dividing cells 
within the tumour, but tend to spare the slowly dividing and inherently resistant CSCs and, 
thus, may not lead to long-term cures [Hellman et al., 2008].  
CSCs may be eliminated by selectively targeted therapies against various self-renewal 
signalling pathways including Notch, Shh, BMI 1 and Wnt signalling pathways [Massard et 
al., 2006]. However, if normal stem cells and CSCs share the same pathways to maintain 
their self-renewal, it would be more complex to selectively target at self-renewal pathways 
of CSCs without any side-effects to normal stem cells. Fortunately, it appears that CSCs are 
more likely to be more dependent on certain putative pathways [Pardal et al., 2003].  
CSCs may be protected from external toxic agents via the over-expression of ABC 
transporter proteins. Therefore, targeting at this protein may be an alternative strategy and, 
thus, a way to overcome chemoresistance. Recently, an in vitro study have shown the benefit 
of gefitinib (Iressa, AstraZeneca), a tyrosine kinase inhibitor, in reversing chemotherapy 
resistance in multidrug resistant breast cancer cells expressing ATP transporters [Yang et al., 
2005]. Also, gefitinib has been recently reported to successfully overcome SN-38-resistance 
in small-cell lung cancer cells in vitro [Takigawa et al., 2007]. 
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Moreover, instead of killing tumour cells with chemotherapy, biological therapy with 
monoclonal antibodies targeted against specific cellular surface molecules or receptors 
should be considered. Targeting at the apoptotic pathway could be an alternative. Cell death 
is generally programmed by apoptosis, including that regulated by CSCs [Baguley, 2006]. 
The elimination of CSCs may be feasible by increasing the ratio of pro-apoptotic to anti-
apoptotic proteins and signal pathways, perhaps targeting at pro-apoptotic members of the 
Bcl2 family [Thompson and Thompson, 2004]. Alternatively, targeting CSCs at the niche 
endothelium would be a possible therapeutic strategy. CSCs niches are likely to be well 
endowed with a blood supply by angiogenesis [Baguley, 2006]. Therefore, blockage of action 
of VEGF signalling with anti-VEGF, bevacizumab (Avastin, Genetech), could be an 
alternative.  
However, all the strategies proposed above are speculative. Published data, so far, has not 
yet confirmed the benefit of these approaches in chemoresistant patients where CSCs are 
believed to be the predominant factor. If CSCs are key molecules responsible for 
chemoresistance, there is an urgent need to enhance both experimental and clinical studies 
to support the use of these biological therapies in chemoresistant breast cancers. It is likely 
that additional agents, following chemotherapy, may be needed to eradicate CSCs, if a good 
long-term outcome is to be achieved. 
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